Literature DB >> 17105688

The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease.

Julia B Ewaschuk1, Qassim Z Tejpar, Isaac Soo, Karen Madsen, Richard N Fedorak.   

Abstract

Abundant evidence indicates that the intestinal microflora have a role in the pathogenesis of inflammatory bowel disease (IBD). The composition of the gut microflora is altered in IBD patients with increased "pathogenic" bacteria and decreased bifidobacteria and lactobacilli. In light of this dysbiosis, various methods have been examined to alter the composition of the intestinal microflora, including the administration of antibiotics and introduction of probiotic species. This article summarizes studies evaluating the efficacy of antibiotics and probiotics in the induction and maintenance of remission of ulcerative colitis, Crohn's disease, and pouchitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17105688     DOI: 10.1007/s11894-006-0039-z

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  53 in total

1.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.

Authors:  P Gionchetti; F Rizzello; A Venturi; P Brigidi; D Matteuzzi; G Bazzocchi; G Poggioli; M Miglioli; M Campieri
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

2.  Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora.

Authors:  J Kuisma; S Mentula; H Jarvinen; A Kahri; M Saxelin; M Farkkila
Journal:  Aliment Pharmacol Ther       Date:  2003-02-15       Impact factor: 8.171

3.  Mucosal flora in inflammatory bowel disease.

Authors:  Alexander Swidsinski; Axel Ladhoff; Annelie Pernthaler; Sonja Swidsinski; Vera Loening-Baucke; Marianne Ortner; Jutta Weber; Uwe Hoffmann; Stefan Schreiber; Manfred Dietel; Herbert Lochs
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

4.  Probiotic bacteria enhance murine and human intestinal epithelial barrier function.

Authors:  K Madsen; A Cornish; P Soper; C McKaigney; H Jijon; C Yachimec; J Doyle; L Jewell; C De Simone
Journal:  Gastroenterology       Date:  2001-09       Impact factor: 22.682

5.  Open label trial of oral clarithromycin in active Crohn's disease.

Authors:  K Leiper; A I Morris; J M Rhodes
Journal:  Aliment Pharmacol Ther       Date:  2000-06       Impact factor: 8.171

6.  Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.

Authors:  Paolo Gionchetti; Fernando Rizzello; Ulf Helwig; Alessandro Venturi; Karen Manon Lammers; Patrizia Brigidi; Beatrice Vitali; Gilberto Poggioli; Mario Miglioli; Massimo Campieri
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

7.  Treatment of ulcerative colitis using fecal bacteriotherapy.

Authors:  Thomas J Borody; Eloise F Warren; Sharyn Leis; Rosa Surace; Ori Ashman
Journal:  J Clin Gastroenterol       Date:  2003-07       Impact factor: 3.062

8.  Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD)

Authors:  R Duchmann; I Kaiser; E Hermann; W Mayet; K Ewe; K H Meyer zum Büschenfelde
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

9.  Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis.

Authors:  Hideki Ishikawa; Ikuko Akedo; Yoshinori Umesaki; Ryuichiro Tanaka; Akemi Imaoka; Toru Otani
Journal:  J Am Coll Nutr       Date:  2003-02       Impact factor: 3.169

Review 10.  Probiotics and the management of inflammatory bowel disease.

Authors:  Richard N Fedorak; Karen L Madsen
Journal:  Inflamm Bowel Dis       Date:  2004-05       Impact factor: 5.325

View more
  15 in total

1.  Probiotic Therapies for IBD.

Authors:  Richard N Fedorak
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

Review 2.  Skin microbiota: a source of disease or defence?

Authors:  A L Cogen; V Nizet; R L Gallo
Journal:  Br J Dermatol       Date:  2008-03       Impact factor: 9.302

Review 3.  Toll-like receptors in inflammatory bowel disease-stepping into uncharted territory.

Authors:  Avi Levin; Oren Shibolet
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

Review 4.  Microbial host interactions in IBD: implications for pathogenesis and therapy.

Authors:  R Balfour Sartor; Marcus Muehlbauer
Journal:  Curr Gastroenterol Rep       Date:  2007-12

Review 5.  Intestinal mucosal barrier function in health and disease.

Authors:  Jerrold R Turner
Journal:  Nat Rev Immunol       Date:  2009-11       Impact factor: 53.106

Review 6.  Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?

Authors:  Georgina L Hold; Megan Smith; Charlie Grange; Euan Robert Watt; Emad M El-Omar; Indrani Mukhopadhya
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

7.  Gut bacteria in health and disease.

Authors:  Eamonn M M Quigley
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-09

8.  Combined probiotic bacteria promotes intestinal epithelial barrier function in interleukin-10-gene-deficient mice.

Authors:  Chen-Zhang Shi; Hong-Qi Chen; Yong Liang; Yang Xia; Yong-Zhi Yang; Jun Yang; Jun-Dong Zhang; Shu-Hai Wang; Jing Liu; Huan-Long Qin
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

Review 9.  The human microbiome: at the interface of health and disease.

Authors:  Ilseung Cho; Martin J Blaser
Journal:  Nat Rev Genet       Date:  2012-03-13       Impact factor: 53.242

Review 10.  Probiotics in the management of colonic disorders.

Authors:  Eamonn M M Quigley
Journal:  Curr Gastroenterol Rep       Date:  2007-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.